Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059551
Filing Date
2024-05-14
Accepted
2024-05-14 16:11:12
Documents
70
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pstx-20240331.htm   iXBRL 10-Q 1868407
2 EX-10.1 pstx-ex10_1.htm EX-10.1 37593
3 EX-10.5 pstx-ex10_5.htm EX-10.5 62204
4 EX-10.6 pstx-ex10_6.htm EX-10.6 25721
5 EX-31.1 pstx-ex31_1.htm EX-31.1 12826
6 EX-31.2 pstx-ex31_2.htm EX-31.2 12808
7 EX-32.1 pstx-ex32_1.htm EX-32.1 8171
8 EX-32.2 pstx-ex32_2.htm EX-32.2 8194
9 GRAPHIC img82316545_0.jpg GRAPHIC 5314
  Complete submission text file 0000950170-24-059551.txt   7410966

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240331.xsd EX-101.SCH 1182181
74 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240331_htm.xml XML 1005169
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39376 | Film No.: 24944446
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)